|
Accrued
Expenses, summarized by major category, as of June 30, 2022 and December 31, 2021 consist of the following:
Schedule
of Accrued Expenses
| |
|
June 30, 2022 |
|
|
December 31, 2021 |
|
| Payroll and incentives |
|
$ |
974 |
|
|
$ |
1,343 |
|
| General and administrative expenses |
|
|
404 |
|
|
|
195 |
|
| Research and development expenses |
|
|
376 |
|
|
|
381 |
|
| Deferred revenue * |
|
|
2,096 |
|
|
|
33 |
|
| Other deferred liabilities ** |
|
|
444 |
|
|
|
899 |
|
| Total |
|
$ |
4,294 |
|
|
$ |
2,851 |
|
| * |
At
June 30, 2022, the balance included $2,063 thousand related to the BioNTech Agreement and
$33 thousand is related to the Genentech Agreement. At December 31, 2021, the balance of
$33 thousand of deferred revenue was related to the Genentech Agreement. The balance of the
BioNTech Agreement will be recognized evenly over the next nine months. (See Note 9 –
Revenue Recognition, Collaboration Agreements and Other).
|
| ** |
At
June 30, 2022, the balance of $444
thousand is related to the CFF Agreement’s deferred liability. At December 31, 2021, the balance of $899
thousand was related to the CFF Agreement’s deferred liability. (See Note 9 – Revenue Recognition, Collaboration
Agreements and Other). |
|